BioSpace News Archive

TAE Life Sciences and AIVITA Biomedical Announce Strategic Partnership to Advance Development of Target Boron Drugs for Glioblastoma.

Spero Health, one of the nation’s largest office-based outpatient opioid treatment providers for individuals in recovery, to expand patient access to Pear’s prescription digital therapeutics (PDTs) for the treatment of substance use disorder (SUD) and opioid use disorder (OUD).

Elpiscience Biopharmaceuticals, Inc. today announced that it will present the latest progress of its innovative molecules and powerful antibody generation platforms at the Biotech Showcase™ conference during J.P. Morgan Week 2023 in San Francisco in January.

IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on January 3, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to twelve newly-hired, non-executive employees.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT.

Therapeutic Solutions International (TSOI) announced novel data and patent filing today on the unanticipated finding that multiple microinjections of myelin basic protein derived peptides together with various agents that block dendritic cell maturation leads to substantially higher suppression of multiple sclerosis symptomology in the experimental autoimmune encephalitis model of the disease as compared to various conventional means of administration.

Eli Lilly and Company (NYSE: LLY) will attend the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023.

Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleotide (ASO) therapies into the intrathecal space.

Immunomic Therapeutics, Inc. announced today that Dr. William Hearl, Chief Executive Officer, will give a presentation entitled, “Dynamic Activation of the Immune System Using UNITE ® Technology, Nucleic Acid-Based Cell Therapies for Immuno-Oncology,” at Biotech Showcase 2023, being held January 9-11, 2023 in San Francisco.

Arugula Sciences, LLC. today announced that it has, in collaboration with its clinical partners, advanced its first therapeutic product, Signature Cord Prime™ (SIG001), with FDA approval for a Phase 1 clinical trial (NCT05234489) in the US.